Loading...
XLONEAH
Market cap60mUSD
Dec 23, Last price  
71.00GBP
1D
0.00%
1Q
-33.64%
Jan 2017
-85.94%
Name

ECO Animal Health Group PLC

Chart & Performance

D1W1MN
XLON:EAH chart
P/E
4,590.59
P/S
53.80
EPS
0.02
Div Yield, %
0.06%
Shrs. gr., 5y
0.39%
Rev. gr., 5y
5.86%
Revenues
89m
+4.82%
17,031,00020,333,00014,703,00016,481,00018,898,00021,768,00027,078,00028,322,00028,985,95431,865,00038,997,00047,138,00061,422,00067,201,00067,253,00072,106,000105,607,00082,195,00085,311,00089,422,000
Net income
1m
+3.97%
2,658,000-42,0002,820,000-784,000391,1001,239,0001,591,0002,218,0002,616,8922,431,1434,094,0006,037,00010,565,0009,315,0007,253,0003,895,0007,337,000-686,0001,008,0001,048,000
CFO
9m
-41.18%
14,282,6002,648,0005,122,000-591,0002,969,0003,335,0008,465,0006,130,0004,333,2056,203,0007,220,0002,488,00011,815,00014,066,0006,273,0004,510,00012,110,000-358,00016,010,0009,417,000
Dividend
Sep 23, 20211 GBP/sh
Earnings
Jul 14, 2025

Profile

ECO Animal Health Group plc, together with its subsidiaries, develops, registers, and markets pharmaceutical products for animals worldwide. The company provides Aivlosin, a macrolide antibiotic for the treatment of enteric and respiratory diseases in pigs and poultry. It also offers generic drugs, such as Ecomectin, Ecoheart, Ecotraz, and Ecomintic, which are endectocides and other antiparasitics for the treatment and prevention of parasites, such as worms, ticks, and lices in cattle, sheep, pigs, horses, and dogs; and Chlortetracycline and Oxytetracycline for treatment of bacterial infections in pigs, poultry, and cattle. ECO Animal Health Group plc was founded in 1972 and is headquartered in New Malden, the United Kingdom.
URL
https://www.ecoanimalhealthgroupplc.com/
IPO date
Sep 26, 1995
Employees
234
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
89,422
4.82%
85,311
3.79%
82,195
-22.17%
Cost of revenue
85,302
80,256
77,668
Unusual Expense (Income)
NOPBT
4,120
5,055
4,527
NOPBT Margin
4.61%
5.93%
5.51%
Operating Taxes
966
1,349
2,094
Tax Rate
23.45%
26.69%
46.26%
NOPAT
3,154
3,706
2,433
Net income
1,048
3.97%
1,008
-246.94%
(686)
-109.35%
Dividends
(2,813)
(1,810)
(2,886)
Dividend yield
4.76%
2.73%
2.63%
Proceeds from repurchase of equity
6
2,581
BB yield
-0.01%
-2.35%
Debt
Debt current
646
884
397
Long-term debt
7,404
7,192
3,026
Deferred revenue
Other long-term liabilities
(1)
Net debt
(14,592)
(13,834)
(11,330)
Cash flow
Cash from operating activities
9,417
16,010
(358)
CAPEX
(502)
(5,981)
(2,887)
Cash from investing activities
(3,416)
(5,981)
(2,884)
Cash from financing activities
(3,691)
(2,402)
(3,305)
FCF
8,139
13,710
(2,274)
Balance
Cash
22,374
21,658
14,314
Long term investments
268
252
439
Excess cash
18,171
17,644
10,643
Stockholders' equity
30,061
32,232
31,029
Invested Capital
79,234
81,370
85,391
ROIC
3.93%
4.44%
2.96%
ROCE
4.17%
5.11%
4.71%
EV
Common stock shares outstanding
69,080
68,640
67,717
Price
0.86
-11.40%
0.97
-40.43%
1.62
-49.77%
Market cap
59,063
-10.83%
66,238
-39.62%
109,702
-49.68%
EV
54,161
64,685
110,656
EBITDA
6,915
7,406
6,520
EV/EBITDA
7.83
8.73
16.97
Interest
764
656
284
Interest/NOPBT
18.54%
12.98%
6.27%